A comparative analysis of endocrine toxicities associated with PD-1, PD-L1, and LAG-3 inhibitors indicates that the risk of adrenal insufficiency is markedly higher with combination regimens, particularly those incorporating LAG-3 blockade [31-33] (Table 1). The gene discussed is LAG3; the disease is Adrenal insufficiency.